查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1511933

基底细胞癌治疗市场规模、份额和趋势分析报告：按治疗类型、地区和细分市场预测，2024-2030年

Basal Cell Carcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 158 Pages | 商品交期: 2-10个工作天内

价格

基底细胞癌治疗市场的成长与趋势：

Grand View Research最新报告显示，预计到2030年，全球基底细胞癌治疗市场规模将达到59.3亿美元，2024年至2030年复合年增长率为10.44%。

这个市场主要是由基底细胞癌盛行率的增加和老年人口的增加所推动的。欧洲皮肤癌基金会估计，基底细胞癌（BCC）的发生率呈增加趋势，欧洲每年每10万人中有50至80例新病例，澳洲每10万人中有250例新病例。癌症患者数量的增加主要是由于总人口和老年人口的增加以及某些社会经济因素造成的。

疾病诊断和治疗的技术进步预计将对市场成长产生积极影响。先进的技术使皮肤科医生能够更准确地诊断患者并有效区分基底细胞癌和其他皮肤病变。例如，2024年，美国FDA核准了人工智慧驱动的光学光谱仪DermaSensor用于检测皮肤癌，包括黑色素瘤、单细胞癌（SCC）和基底细胞癌（BCC）。这项技术可以帮助初级保健临床医生识别需要立即切片检查或专科治疗的患者，从而减少某些地区漫长的等待时间和皮肤科医生的短缺。此类诊断工具的增加使用预计将提高未来的诊断和治疗率，从而推动对用于治疗基底细胞癌的药物的需求。

此外，不断增长的老年人口正在推动对基底细胞癌治疗的需求，包括手术、放射治疗、局部化疗、内服药物和化学换肤。发生基底细胞癌的主要原因是反覆暴露于紫外线 (UV) 辐射。老年人比年轻人更容易罹患基底细胞癌，因为他们接触更多的紫外线。老年人皮肤癌（尤其是基底细胞癌）的风险增加，因为随着老龄化和免疫系统的减弱，紫外线辐射和其他致癌物质更容易破坏 DNA。根据2023年发表在《老年肿瘤学杂誌》上的一项研究，美国每年有超过10万名BCC患者在生命的最后一年接受治疗。因此，预计老年人口的增加将在预测期内推动市场成长。

基底细胞癌治疗报告亮点

  • 2023年，外科手术领域占市场最大的收益占有率。这是由于疾病的发生率和盛行率不断增加，以及对安全有效的手术治疗的高需求。
  • 在局部化疗中，5-Fluorouracil（5-FU）细分市场在2023年占据最大市场份额。这是由于开发并推出了用于治疗 BCC 患者的新非专利药 5-Fluorouracil(5-FU)。
  • 由于先进的医疗基础设施、基底细胞癌盛行率的增加以及有利于新产品研发的法规环境等因素，北美在市场上占据主导地位。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章：基底细胞癌治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 基底细胞癌治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章基底细胞癌治疗市场：治疗类型估计与趋势分析

  • 全球基底细胞癌治疗市场：治疗型仪表板
  • 全球基底细胞癌治疗市场：治疗类型变异分析
  • 全球基底细胞癌治疗市场：依治疗类型和收益
  • 外科手术
  • 放射治疗 (RT)
  • 病灶内注射
  • 局部化疗
  • 口服药物
  • 静脉注射药物
  • 化学换肤治疗

第五章基底细胞癌治疗市场：按治疗类型分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第六章 竞争状况

  • 公司/竞争对手分类
  • 参与企业概况
  • 财务概览
  • 治疗类型基准
  • 2023 年企业市场占有率分析
  • 策略规划
  • 公司简介
    • Bausch Health Companies Inc.
    • Almirall, SA
    • Genentech, Inc.（Subsidiary of F. Hoffmann-La Roche AG）
    • Novartis AG.
    • Regeneron Pharmaceuticals Inc.
    • Dr Reddy's Laboratories.
    • Taro Pharmaceuticals Ltd.
    • Accord Healthcare Limited（Subsidiary of Intas Pharmaceuticals）
Product Code: GVR-4-68040-170-1

Basal Cell Carcinoma Treatment Market Growth & Trends:

The global basal cell carcinoma treatment market size is anticipated to reach USD 5.93 billion by 2030, growing at a CAGR of 10.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of basal cell carcinoma and the rising geriatric population. The European Skin Cancer Foundation estimates that the incidence of basal cell carcinoma (BCC) is 50 to 80 new cases per 100,000 people in Europe and 250 cases per 100,000 people in Australia annually, with an increasing trend. The increase in the number of cancer cases can primarily be attributed to the growing overall & geriatric population and certain socioeconomic factors.

Technological advancement in the diagnosis and treatment of disease is anticipated to positively impact market growth. With advanced technologies, dermatologists can more accurately diagnose patients and effectively differentiate basal cell carcinoma from other skin lesions. For instance, in 2024, the U.S. FDA approved DermaSensor, an AI-powered light spectroscopy instrument for detecting skin cancer, including melanoma, single cell carcinoma (SCC), and basal cell carcinoma (BCC). This technique can help primary care clinicians identify patients who require rapid attention for a biopsy and specialist care, thereby alleviating high wait times and the shortage of dermatologists in certain places. The growing use of such diagnostic tools is expected to increase the diagnostic and treatment rates in the future, driving demand for medicines used for the treatment of basal cell carcinoma.

Furthermore, the increase in the geriatric population is driving the demand for treatment of BCC, including surgery, radiotherapy, topical chemotherapy, oral medications, and chemical peeling. The main cause of developing BCC is repeated exposure to Ultraviolet (UV) light. The elderly population has a higher chance of acquiring BCC than younger people as they have been exposed to UV rays for longer during their lifetime. Due to aging and reduced immune system function, UV radiation and other carcinogenic factors can break the DNA more easily, increasing the risk of skin cancer, especially BCC, in older persons. According to a study published in the Journal of Geriatric Oncology in 2023, over 100,000 patients with BCC are treated annually in their final year of life in the U.S. However, clinical practice guidelines hardly ever take age & comorbidities into account. Thus, a growing geriatric population is expected to drive market growth during the forecast period.

Basal Cell Carcinoma Treatment Report Highlights:

  • The surgery segment held the largest revenue share of the market in 2023. This can be attributed to the increasing incidence and prevalence of disease and the high demand for surgery for treatment owing to high safety and efficacy.
  • In topical chemotherapy, the 5-fluorouracil (5-FU) segment held the largest share of the market in 2023. This can be attributed to the development and launch of a novel generic version of 5-fluorouracil (5-FU) to treat BCC patients.
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, increasing prevalence of basal cell carcinoma, and favorable regulatory environment for R&D of novel products.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment Type
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Type Outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Basal Cell Carcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of target diseases
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Rising geriatric population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Adverse effects associated with treatment.
      • 3.2.2.2. High cost of treatment
  • 3.3. Basal Cell Carcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Basal Cell Carcinoma Treatment Market: Treatment Type Estimates & Trend Analysis

  • 4.1. Global Basal Cell Carcinoma Treatment Market: Treatment Type Dashboard
  • 4.2. Global Basal Cell Carcinoma Treatment Market: Treatment Type Movement Analysis
  • 4.3. Global Basal Cell Carcinoma Treatment Market By Treatment Type, Revenue
  • 4.4. Surgery
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Mohs Surgery
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Surgical Excision
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Electrodesiccation and Curettage (ED&C)
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Radiotherapy (RT)
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Intralesional Injections
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Topical Chemotherapy
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.2. 5-fluorouracil (5-FU)
      • 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.3. Tirbanibulin (Klisyri)
      • 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.4. Imiquimod (Zyclara)
      • 4.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Oral Medications
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.2. Vismodegib (Erivedge)
      • 4.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.3. Sonidegib (Odomzo)
      • 4.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Intravenous Medications
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Chemical Peeling Treatment
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million).

Chapter 5. Basal Cell Carcinoma Treatment Market: Regional Estimates & Trend Analysis By Treatment Type

  • 5.1. Regional Dashboard
  • 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.3. North America
    • 5.3.1. U.S.
      • 5.3.1.1. Key country dynamics
      • 5.3.1.2. Regulatory framework/ reimbursement structure
      • 5.3.1.3. Competitive scenario
      • 5.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.2. Canada
      • 5.3.2.1. Key country dynamics
      • 5.3.2.2. Regulatory framework/ reimbursement structure
      • 5.3.2.3. Competitive scenario
      • 5.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.3. Mexico
      • 5.3.3.1. Key country dynamics
      • 5.3.3.2. Regulatory framework/ reimbursement structure
      • 5.3.3.3. Competitive scenario
      • 5.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Key country dynamics
      • 5.4.1.2. Regulatory framework/ reimbursement structure
      • 5.4.1.3. Competitive scenario
      • 5.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Regulatory framework/ reimbursement structure
      • 5.4.2.3. Competitive scenario
      • 5.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. France
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Regulatory framework/ reimbursement structure
      • 5.4.3.3. Competitive scenario
      • 5.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Regulatory framework/ reimbursement structure
      • 5.4.4.3. Competitive scenario
      • 5.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Key country dynamics
      • 5.4.5.2. Regulatory framework/ reimbursement structure
      • 5.4.5.3. Competitive scenario
      • 5.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Denmark
      • 5.4.6.1. Key country dynamics
      • 5.4.6.2. Regulatory framework/ reimbursement structure
      • 5.4.6.3. Competitive scenario
      • 5.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Key country dynamics
      • 5.4.7.2. Regulatory framework/ reimbursement structure
      • 5.4.7.3. Competitive scenario
      • 5.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.8. Norway
      • 5.4.8.1. Key country dynamics
      • 5.4.8.2. Regulatory framework/ reimbursement structure
      • 5.4.8.3. Competitive scenario
      • 5.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework/ reimbursement structure
      • 5.5.1.3. Competitive scenario
      • 5.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. China
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. India
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Regulatory framework/ reimbursement structure
      • 5.5.3.3. Competitive scenario
      • 5.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Regulatory framework/ reimbursement structure
      • 5.5.4.3. Competitive scenario
      • 5.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.5. South Korea
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Regulatory framework/ reimbursement structure
      • 5.5.5.3. Competitive scenario
      • 5.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.6. Thailand
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Regulatory framework/ reimbursement structure
      • 5.5.6.3. Competitive scenario
      • 5.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework/ reimbursement structure
      • 5.6.1.3. Competitive scenario
      • 5.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Argentina
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. MEA
    • 5.7.1. South Africa
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework/ reimbursement structure
      • 5.7.1.3. Competitive scenario
      • 5.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework/ reimbursement structure
      • 5.7.4.3. Competitive scenario
      • 5.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company/Competition Categorization
  • 6.2. Participant Overview
  • 6.3. Financial Overview
  • 6.4. Treatment Type Benchmarking
  • 6.5. Company Market Share Analysis, 2023
  • 6.6. Strategy Mapping
  • 6.7. Company Profiles
    • 6.7.1. Bausch Health Companies Inc.
      • 6.7.1.1. Company overview
      • 6.7.1.2. Financial performance
      • 6.7.1.3. Product benchmarking
      • 6.7.1.4. Strategic initiatives
    • 6.7.2. Almirall, S.A.
      • 6.7.2.1. Company overview
      • 6.7.2.2. Financial performance
      • 6.7.2.3. Product benchmarking
      • 6.7.2.4. Strategic initiatives
    • 6.7.3. Genentech, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
      • 6.7.3.1. Company overview
      • 6.7.3.2. Financial performance
      • 6.7.3.3. Product benchmarking
      • 6.7.3.4. Strategic initiatives
    • 6.7.4. Novartis AG.
      • 6.7.4.1. Company overview
      • 6.7.4.2. Financial performance
      • 6.7.4.3. Product benchmarking
      • 6.7.4.4. Strategic initiatives
    • 6.7.5. Regeneron Pharmaceuticals Inc.
      • 6.7.5.1. Company overview
      • 6.7.5.2. Financial performance
      • 6.7.5.3. Product benchmarking
      • 6.7.5.4. Strategic initiatives
    • 6.7.6. Dr Reddy's Laboratories.
      • 6.7.6.1. Company overview
      • 6.7.6.2. Financial performance
      • 6.7.6.3. Product benchmarking
      • 6.7.6.4. Strategic initiatives
    • 6.7.7. Taro Pharmaceuticals Ltd.
      • 6.7.7.1. Company overview
      • 6.7.7.2. Financial performance
      • 6.7.7.3. Product benchmarking
      • 6.7.7.4. Strategic initiatives
    • 6.7.8. Accord Healthcare Limited (Subsidiary of Intas Pharmaceuticals)
      • 6.7.8.1. Company overview
      • 6.7.8.2. Financial performance
      • 6.7.8.3. Product benchmarking
      • 6.7.8.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 4 U.S. basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 5 Canada basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 6 Mexico basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 7 Europe basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 8 Europe basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 9 Germany basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 10 UK basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 11 France basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 12 Italy basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 13 Spain basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 14 Denmark basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 15 Sweden basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 16 Norway basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 19 China basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 20 Japan basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 21 India basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 22 South Korea basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 23 Australia basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 24 Thailand basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 25 Latin America basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 26 Latin America basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 27 Brazil basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 28 Argentina basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 29 MEA basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 30 MEA basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 31 South Africa basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 33 UAE basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 34 Kuwait basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Basal cell carcinoma treatments market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment.
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment type segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Parent market (USD Billion)
  • Fig. 12 Market dynamics
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 PESTLE analysis
  • Fig. 15 Basal cell carcinoma treatment market: Treatment type outlook key takeaways
  • Fig. 16 Basal cell carcinoma treatment market: Treatment type movement analysis
  • Fig. 17 Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Mohs surgery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Tumor removal procedures (including skin cancer)
  • Fig. 20 Surgical excision market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Electrodesiccation and Curettage (ED&C) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Radiotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Intralesional injections market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Topical chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 5-fluorouracil (5-FU) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Tirbanibulin (Klisyri) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Imiquimod (Zyclara) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Oral medications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Vismodegib (Erivedge) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Sonidegib (Odomzo) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Intravenous medications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Chemical peeling treatment minimally invasive procedures, 2018 - 2030 (USD Million)
  • Fig. 33 Chemical peeling treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Basal cell carcinoma treatment market revenue, by region, 2023 & 2030 (USD Million)
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 Regional marketplace: Key takeaways
  • Fig. 37 North America basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 U.S. basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Canada basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Mexico basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Regulatory framework
  • Fig. 45 Europe basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 UK basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Germany basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 France basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Spain basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Italy basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Denmark basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Sweden basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Norway basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Rest of Europe basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Japan pharmaceutical registration
  • Fig. 67 Key country dynamics
  • Fig. 68 China basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Regulatory details: China
  • Fig. 70 Key country dynamics
  • Fig. 71 India basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Registration details: India
  • Fig. 73 Key country dynamics
  • Fig. 74 Australia basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Drug pricing: Australia
  • Fig. 76 Contribution of PBS by disease
  • Fig. 77 Key country dynamics
  • Fig. 78 Thailand basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 South Korea basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Reimbursement scenario: South Korea
  • Fig. 82 Rest of Asia Pacific basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Brazil basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Argentina basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Argentina pharmaceuticals registration details
  • Fig. 89 Argentina pharmaceuticals reimbursement details
  • Fig. 90 Rest of Latin America basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 91 MEA basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 South Africa basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 Regulatory framework: South Africa
  • Fig. 95 Regulatory framework: South Africa drug registration fees
  • Fig. 96 Key country dynamics
  • Fig. 97 Saudi Arabia basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 UAE basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 Kuwait basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 102 Regulatory framework: Kuwait
  • Fig. 103 Rest of MEA basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 104 Market participant categorization
  • Fig. 105 Heat map analysis
  • Fig. 106 Strategic framework